Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
Lionsgate is developing a sequel to the 2015 supernatural action film 'The Last Witch Hunter' with Vin Diesel and Michael Caine expected to reprise their roles.
Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
Lionsgate is developing a sequel to the 2015 supernatural action film 'The Last Witch Hunter' with Vin Diesel and Michael Caine expected to reprise their roles.